Introduction
============

A novel human coronavirus first detected during an unexplained cluster of pneumonia cases in Wuhan, China in December 2019 has spread globally.[@ref1] [@ref2] As of 22 March 2020, the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (genus *Betacoronavirus*, family Coronaviridae) has been reported in 190 countries with more than 300 000 confirmed cases and 14 510 deaths.[@ref3] A predominant number of cases has occurred in China,[@ref4] with early clinical characterisation showing that 13.8% of those infected developed severe disease, and death occurred in 2.3% of the cases.

Viral load measurements from tissue samples are indicative of active virus replication and are routinely used to monitor severe viral respiratory tract infections, including clinical progression, response to treatment, cure, and relapse.[@ref5] [@ref6] [@ref7] One study described changes in viral loads in samples from the upper respiratory tract of 18 patients with coronavirus disease 2019 (covid-19, an infectious disease caused by SARS-CoV-2), showing that the viral loads were equally high among asymptomatic patients and those with symptoms.[@ref8] However, the viral load dynamics in lower respiratory tract and other tissue samples and the relation between viral load and disease severity is unknown---information that are important for the formulation of disease control strategies and clinical treatment.

We systematically estimated the viral loads in more than 3000 samples collected from 96 patients after admission who were infected with SARS-CoV-2, and analysed the temporal change in viral loads and the correlation between viral loads in different sample types and disease severity.

Methods
=======

Study design
------------

This was a retrospective cohort study of patients with laboratory confirmed covid-19 admitted consecutively to the First Affiliated Hospital, College of Medicine, Zhejiang University from 19 January 2020 to 15 February 2020. This major general hospital has 3000 beds and serves as a designated hospital for patients with covid-19 in Zhejiang province.

Sample collection and laboratory confirmation
---------------------------------------------

After admission, respiratory, serum, stool, and urine samples were collected daily whenever possible to determine the amount of SARS-CoV-2 ribonucleic acid (RNA) by polymerase chain reaction (PCR) analysis. Sputum samples were collected from the respiratory tract of patients with sputum, and saliva after deep cough was collected from patients without sputum.[@ref9] Blood samples were collected in a special whole blood collection tube, and urine and stool samples were collected in a special sterile container. All medical staff were equipped with personal protection equipment for biosafety level 3 during sampling, including solid front wraparound gowns, goggles, and N95 respirators.

Viral RNA was extracted using the MagNA Pure 96 (Roche, Basel, Switzerland), and quantitative reverse transcription PCR (qRT-PCR) was performed using a China Food and Drug Administration approved commercial kit specific for SARS-CoV-2 detection (BoJie, Shanghai, China). The detection limit of the ORFab1 qRT-PCR assays was about 1000 copies per millilitre. Samples with cycle threshold (Ct) values of ≤38.0 were considered positive for SARS-CoV-2 RNA. Samples with Ct values \>38.0 were repeated, and samples with repeated Ct values of \>38.0 and samples with undetectable Ct values were considered negative. Viral load was calculated by plotting Ct values onto the standard curve constructed based on the standard product.

Data collection
---------------

The research team of the First Affiliated Hospital, College of Medicine, Zhejiang University analysed the medical records of patients. Epidemiological, clinical, and laboratory characteristics and treatment and outcomes data were obtained through data collection forms from hospital electronic medical records. A trained team of doctors reviewed the data. The clinical data included personal characteristics, comorbidities, date of symptom onset, symptoms and signs, timing of antiviral treatment, and progression and resolution of clinical illness. Comorbidities documented included diabetes mellitus, heart disease, chronic lung disease, renal failure, liver disease, HIV infection, cancer, and receipt of immunosuppressive treatment, including corticosteroids. We considered that the symptoms started when any of fever, cough, chills, dizziness, headache, and fatigue appeared.

The severity of illness was evaluated according to the sixth edition of the Guideline for Diagnosis and Treatment of SARS-CoV-2 issued by the National Health Commission of the People's Republic of China.[@ref10] Mild cases include non-pneumonia or mild pneumonia. Severe disease refers to dyspnoea, respiratory rate ≥30/min, blood oxygen saturation ≤93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio \<300, or lung infiltrates \>50% within 24 to 48 hours. Patients who test negative for SARS-CoV-2 for two consecutive days in respiratory samples are considered to be clear of infection.

Statistical analysis
--------------------

For most variables, we calculated descriptive statistics, such as medians with interquartile ranges (for data with skewed distribution) and proportions (percentages). Statistical comparisons between the mild and severe groups were evaluated by *t* test, analysis of variance, Mann-Whitney U tests, and Kruskal-Wallis tests when appropriate. To explore the variation of viral load across the days since symptom onset, we calculated the median of viral load each day, followed by fitting smooth lines using a loess method.[@ref11] For this analysis, we only included patients with viral loads monitored for more than five days in respiratory and stool samples. Statistical analyses were performed using the R software package, v3.6.2. A P value of \<0.05 was considered significant.

Patient and public involvement
------------------------------

This was a retrospective case series study and no patients were directly involved in the study design, setting the research questions, or the outcome measures. No patients were asked to advise on interpretation or writing up of results.

Results
=======

[Table 1](#tbl1){ref-type="table"} shows the clinical characteristics of 96 patients with confirmed covid-19: 22 with mild disease and 74 with severe disease. The median age was 55 years (interquartile range 44.3-64.8). Of the patients infected in Wuhan, a significantly higher proportion were in the severe group (35%) than in the mild group (9%). Hypertension (36%) and diabetes mellitus (11%) were the most common underlying disease. Most of the patients developed fever (89%) and cough (56%). Overall, 78 (81%) patients received glucocorticoids and 33 (34%) antibiotic treatment. All patients received antiviral treatment comprising interferon α inhalation, lopinavir-ritonavir combination, arbidol, favipiravir, and darunavir-cobicistat combination. Among them, 63 (66%) started antiviral treatment within five days from illness onset and 29 (30%) more than five days after illness onset. Thirty (41%) patients with severe disease were admitted to the intensive care unit. By 20 March, all patients tested negative for SARS-CoV-2, nine (9% of all patients) patients with severe disease were still in hospital, and no deaths had occurred. Supplementary figure S1 shows the outcome among patients infected with SARS-CoV-2, and supplementary table S1 the laboratory findings.

###### 

Personal and clinical characteristics of patients with severe acute respiratory syndrome coronavirus 2 infection by severity of disease

  Characteristics                                          Total (n=96)     Disease severity   P value        
  -------------------------------------------------------- ---------------- ------------------ -------------- ---------
  Median (interquartile range) age (years)                 55 (44.3-64.8)   47.5 (36.8-56.3)   57 (47.5-66)   0.01
  Men                                                      58 (60)          9 (41)             49 (66)        0.03
  Infected in Wuhan                                        28 (29)          2 (9)              26 (35)        0.01
  Underlying diseases:                                                                                        
   Hypertension                                            35 (36)          4 (18)             31 (42)        0.04
   Diabetes mellitus                                       11 (11)          1 (5)              10 (14)        0.44
   Heart disease                                           7 (7)            0 (0)              7 (9)          0.30
   Lung disease                                            4 (4)            0 (0)              4 (5)          0.57
   Liver disease                                           3 (3)            1 (5)              2 (3)          0.55
   Renal disease                                           1 (1)            0 (0)              1 (1)          1.00
   Malignancy                                              1 (1)            0 (0)              1 (1)          1.00
   Immune compromise                                       1 (1)            0 (0)              1 (1)          1.00
  Symptoms:                                                                                                   
   Fever                                                   85 (89)          17 (77)            68 (92)        0.13
   Cough                                                   54 (56)          12 (55)            42 (57)        0.85
   Sputum                                                  26 (27)          7 (32)             19 (26)        0.59
   Chest distress                                          12 (13)          2 (9)              10 (14)        0.85
   Dizziness                                               7 (7)            0 (0)              7 (9)          0.30
   Headache                                                4 (4)            0 (0)              4 (5)          0.57
   Nausea                                                  5 (5)            2 (9)              3 (4)          0.32
   Vomiting                                                2 (2)            0 (0)              2 (3)          1.00
   Diarrhoea                                               10 (10)          0 (0)              10 (14)        0.15
   Myalgia                                                 19 (20)          6 (27)             13 (18)        0.49
   Fatigue                                                 9 (9)            1 (5)              8 (11)         0.64
  Treatment:                                                                                                  
   Gammaglobulin                                           53 (55)          4 (18)             49 (66)        \<0.001
   Glucocorticoids                                         78 (81)          9 (41)             69 (93)        \<0.001
   Antibiotics                                             33 (34)          1 (5)              32 (43)        0.001
   Antivirals                                              96 (100)         22 (100)           74 (100)       NC
  Time from illness onset to antiviral treatment (days):                                                      
   ≤5                                                      63 (66)          14 (64)            49 (66)        0.82
   \>5                                                     29 (30)          8 (36)             21 (28)        0.58
  Disease severity/support:                                                                                   
   Bilateral pulmonary infiltrates                         80 (83)          12 (55)            68 (92)        \<0.001
   Invasive mechanical ventilation                         10 (10)          0 (0)              10 (14)        0.15
   ECMO                                                    5 (5)            0 (0)              5 (7)          0.59
   Intensive care unit admission                           30 (31)          0 (0)              30 (41)        \<0.001

ECMO=extracorporeal membrane oxygenation; NC=not calculable.

SARS-CoV-2 detection rates during disease progression and between sample types
------------------------------------------------------------------------------

A total of 1846 respiratory samples (668 sputum and 1178 saliva) were collected (average 18 samples per patient (range 3-40 samples)); 842 stool samples (7 samples per patient (1-32 samples)); 629 serum samples (7 samples per patient (1-20 samples)), and 180 urine samples (1 sample for each patient (1-6 samples)). Supplementary figure S2 shows the daily collection of different sample types.

SARS-CoV-2 infection was confirmed in all 96 patients by testing respiratory samples. Of these patients, viral nucleic acid was detected in the stool samples of 59% and serum samples of 41%. Rates of SARS-CoV-2 detection in the respiratory samples gradually decreased from 95% in the first week of symptom onset to 54% in he fourth week, with subsequent respiratory samples showing negative results, whereas the positive rate in stool samples and serum samples gradually increased from the first week and then decreased from the third week. In addition, the rate of detection in serum samples was higher in patients with severe disease than in patients with mild disease (45% *v* 27%), but the difference was not significant. The detection rate in stool did not differ between patients with mild disease and patients with severe disease. Only one urine sample collected from a critically ill patient on day 10 was positive for SARS-CoV-2 ([table 2](#tbl2){ref-type="table"}).

###### 

Detection of severe acute respiratory syndrome coronavirus 2 in patients with mild or severe disease at different stages after symptom onset in different sample types. Values are numbers affected/number tested (%) unless stated otherwise

  Sample types      After admission   Weeks since onset of symptoms   P values                               
  ----------------- ----------------- ------------------------------- ------------ ------------ ------------ ---------
  All patients:                                                                                              
   Respiratory      96/96 (100)       42/44 (95)                      74/90 (82)   64/89 (72)   31/57 (54)   \<0.001
   Stool            55/93 (59)        9/23 (39)                       28/59 (47)   32/71 (45)   20/57 (35)   0.54
   Serum            39/95 (41)        5/36 (14)                       20/85 (23)   19/85 (22)   5/55 (9)     0.12
   Urine            1/67 (1)          0/15 (0)                        1/53 (2)     0/21 (0)     0/19 (0)     NC
  Mild disease:                                                                                              
   Respiratory      22/22 (100)       11/12 (92)                      15/21 (71)   9/19 (47)    4/9 (44)     0.04
   Stool            13/22 (59)        2/7 (29)                        8/16 (50)    10/17 (59)   5/9 (56)     0.62
   Serum            6/22 (27)         0/9 (0)                         3/19 (16)    2/17 (12)    0/8 (0)      0.67
   Urine            0/19 (0)          0/3 (0)                         0/15 (0)     0/7 (0)      0/3 (0)      NC
  Severe disease:                                                                                            
   Respiratory      74/74 (100)       31/32 (97)                      59/69 (86)   55/70 (79)   27/48 (56)   \<0.001
   Stool            42/71 (59)        7/16 (44)                       20/43 (47)   22/54 (41)   15/48 (31)   0.49
   Serum            33/73 (45)        5/27 (19)                       17/66 (26)   17/68 (25)   5/47 (11)    0.20
   Urine            1/48 (2)          0/12 (0)                        1/38 (3)     0/14 (0)     0/16 (0)     NC

NC=not calculable.

Correlation between viral duration in different sample types and disease severity
---------------------------------------------------------------------------------

The median duration of virus in stool samples (22 days, interquartile range 17-31 days) was significantly longer than in respiratory (18 days, 13-29 days; P=0.02) and serum samples (16 days, 11-21 days; P\<0.001) ([fig 1](#f1){ref-type="fig"}). In the respiratory samples, the median duration of virus in patients with severe disease (21 days, 14-30 days) was significantly longer than in patients with mild disease (14 days, 10-21 days; P=0.04) ([fig 1](#f1){ref-type="fig"}), whereas no significant difference was observed in the duration of virus between stool and serum samples among patients with different disease severities ([fig 1](#f1){ref-type="fig"}). Supplementary figures S3-S5 show the duration of virus in different sample types in each patient.

![Duration of detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by sample types and disease severity. Coloured bars represent medians and black bars represent interquartile ranges](zhes055740.f1){#f1}

Correlation between viral load in different sample types and disease severity
-----------------------------------------------------------------------------

Viral load differed significantly by sample type, with respiratory samples showing the highest, followed by stool samples, and serum samples showing the lowest ([fig 2](#f2){ref-type="fig"}). In respiratory samples, patients with severe disease had significantly higher viral loads than patients with mild disease ([fig 2](#f2){ref-type="fig"}). Viral loads in stool and serum samples showed no significant difference between patients with mild disease and patients with severe disease ([fig 2](#f2){ref-type="fig"}).

![Comparison of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load by sample types and disease severity. Coloured bars represent medians and black bars represent interquartile ranges](zhes055740.f2){#f2}

Using a loess regression analysis, we found that in the mild group, the viral load in respiratory samples was greater during the initial stages of the disease, reached a peak in the second week from disease onset, and was followed by lower loads ([fig 3](#f3){ref-type="fig"}). In the severe group, however, the viral load in respiratory samples continued to be high during the third and fourth weeks after disease onset ([fig 3](#f3){ref-type="fig"}). The viral load of stool samples was highest during the third and fourth weeks after disease onset ([fig 3](#f3){ref-type="fig"}).

![Smooth lines were fitted using loess method to explore the variation of viral load of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across the days since symptoms onset in respiratory samples from patients with mild and severe disease and in stool samples](zhes055740.f3){#f3}

Factors associated with duration of virus and viral load
--------------------------------------------------------

We found that types and timeliness of antiviral treatments had no overall effect on the duration of the virus and viral load. In the severe group, the duration of the virus was significantly higher in patients treated with glucocorticoids continuously for more than 10 days than in patients treated with glucocorticoids continuously for less than 10 days, whereas different treatments had no effect on viral load (supplementary table S2). When patients with severe disease were stratified, the duration of the virus was significantly longer in men than in women, and significantly longer in patients older than 60 years than younger ([fig 4](#f4){ref-type="fig"}).

![Association between sex and age and duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Coloured bars represent medians and black bars represent interquartile ranges](zhes055740.f4){#f4}

Discussion
==========

We have systematically described the clinical characteristics of 96 patients with covid-19 and described the dynamic changes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) loads and disease progression in 3497 samples of multiple types, revealing the interaction between SARS-CoV-2 replication and clearance by host defence mechanisms. The median duration of virus in respiratory samples was 18 days, which was consistent with the median duration of 20 days for Middle East respiratory syndrome (MERS).[@ref12] Peak viral shedding in respiratory specimens of patients with severe acute respiratory syndrome (SARS) occurred after about 10 to 12 days from symptom onset,[@ref13] [@ref14] which is similar to the peak observed for SARS-CoV-2 in our study. Consistent with earlier reports of SARS-CoV-2,[@ref15] we found differences in the viral load in patients with different disease severities, those with severe disease showing a significantly higher viral load than those with mild disease, which suggests that viral load can be used to assess prognosis.

Studies have found that the peak load of SARS-CoV-2 in upper respiratory tract specimens was during the early stages of the disease[@ref8] [@ref16]; however, we found that the duration of virus shedding in lower respiratory tract samples was longer, and peak viral shedding occurred after about two weeks from symptom onset. These findings are important for effective control and prevention of the epidemic as it suggests strict management of the whole disease process in patients with SARS-CoV-2. In this study, we also found that the viral load in patients with severe disease was significantly higher than in patients with mild disease, suggesting that high viral load might be a risk factor for severe disease.

Active replication of SARS in the gut has been shown through live virus isolation.[@ref17] During 2003, the prevalence of SARS RNA in stool samples was so high that testing of stool was proposed as a reliable and sensitive way to routinely diagnose the disease,[@ref18] [@ref19] whereas MERS RNA was found in only 15% of stool samples, with a low RNA concentration.[@ref20] In this study, we detected SARS-CoV-2 in the stool samples from 59% of patients and found that the duration of virus was longer and viral load peaked later in stool samples compared with respiratory samples. Based on this study, we think the role of faecal excretion in the spread of SARS-CoV-2 cannot be ignored; however, the importance of high detection in stool samples in the prevention and control of the SARS-CoV-2 epidemic requires comprehensive and careful evaluation. We rarely found SARS-CoV-2 RNA in urine samples in this study, although viral RNA detection rates of up to 50% have been found in the urine of patients with SARS.[@ref18] [@ref19]

A clear difference between SARS and SARS-CoV-2 was in the detection of viral RNA in serum. Evidence has been found of SARS virus replicating in circulating lymphocytes, monocytes, macrophages, and dendritic cells, albeit at low levels.[@ref21] [@ref22] [@ref23] In some studies, up to 79% of serum samples were found to contain SARS RNA during the first week of illness, and around 50% during the second week.[@ref24] [@ref25] [@ref26] The rates were similar in MERS.[@ref20] In this study, we found that the detection rate of SARS-CoV-2 in serum was only 41%.

At present, the therapeutic effect of glucocorticoids and antiviral drugs in patients with SARS-CoV-2 is unclear.[@ref27] [@ref28] We found that the duration of treatment with glucocorticoids was positively correlated with viral duration in patients with severe disease. As we did not analysis the type and dose of antiviral drugs and glucocorticoids, however, we cannot evaluate the effect of antiviral drugs and glucocorticoids. Monitoring the effectiveness of antiviral drugs and glucocorticoids needs to be validated by multicentre randomised studies.

A sex dependent increase in disease severity after infection with pathogenic coronavirus was reported for both SARS and MERS,[@ref29] [@ref30] and this was also found for SARS-CoV-2.[@ref31] In this study, we found that the duration of virus was significantly longer in men than in women. Our results shed light on the causes of disease severity in men in terms of the duration of the virus. In addition to differences in immune status between men and women, it has also been reported to be related to differences in hormone levels.[@ref32] In this study, we also found a correlation between age and duration of virus, which partly explains the high rate of severe illness in patients older than 60 years. This is partly because of immunosenescence.[@ref33] Another reason is that older people have higher levels of angiotensin converting enzyme 2 in their alveoli,[@ref34] which is thought to be a receptor for novel coronaviruses.

Limitations of this study
-------------------------

Our study has several limitations. Firstly, this study is a single centre cohort study, and the sample size was insufficient to compare treatment effects in different subgroups, which could lead to an unbalanced distribution of confounders when evaluating viral shedding and viral load. Secondly, viral load is influenced by many factors. The quality of collected samples directly affects the viral load, so the study of viral load only partly reflects the amount of virus in the body. Thirdly, polymerase chain reaction (PCR) cannot distinguish between viable and non-viable virus and does not reflect the replication level of the virus in different tissue. However, PCR has higher sensitivity, is easy to perform, and is widely used in the detection of viral load.[@ref35] In addition, only collecting samples from patients who remain in hospital could overinflate estimates of viral load and duration at a later time point. Finally, since accurate diagnosis was not available during the early stages of the epidemic, stool and urine samples of the earliest infected patients were not collected until early February, hence we recruited patients with positive respiratory samples and could not evaluate patients with negative respiratory samples against other sample types.

Conclusion
----------

The duration of SARS-CoV-2 is significantly longer in stool samples than in respiratory and serum samples, highlighting the need to strengthen the management of stool samples in the prevention and control of the epidemic, especially for patients in the later stages of the disease. Compared with patients with mild disease, those with severe disease showed longer duration of SARS-CoV-2 in respiratory samples, higher viral load, and a later shedding peak. These findings suggest that reducing viral loads through clinical means and strengthening management during each stage of severe disease should help to prevent the spread of the virus.

### What is already known on this topic

1.  As of 9 April 2020, more than 1.5 million people globally have been affected by covid-19, and the numbers continue to increase rapidly

2.  SARS-CoV-2 viral loads have been reported from respiratory, stool, serum, and urine samples in a small number of patients; however, changes in viral load during disease progression of different severities is not known

### What this study adds

1.  The duration of SARS-CoV-2 is significantly longer in stool samples than in respiratory and serum samples, highlighting the need to strengthen the management of stool samples in the prevention and control of the epidemic

2.  The virus persists longer with higher load and peaks later in the respiratory tissue of patients with severe disease

3.  To prevent transmission of SARS-CoV-2 it is therefore necessary to carry out strict management during each stage of severe disease
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